IndusInd Bank Q1 FY27 Results Analysis: PAT Surges 72%, NIM Expands (INDUSINDBK)
IndusInd Bank Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 13,096.47 Cr (-9.18% YoY) and PAT growth of +71.68% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 22, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 13,096.47 Cr (-9.18% YoY) |
| PAT (Q1) | Rs. 1,037.05 Cr (+71.68% YoY) |
| EPS (Q1) | Rs. 13.31 (+71.74% YoY) |
| Market cap | Rs. 78,297.87 Cr |
| CMP | Rs. 1,005.50 |
Quarter Snapshot
IndusInd Bank reported a strong quarter with NIM expansion, cost-to-income improvement, and asset quality gains driving a 72% YoY PAT surge. However, total income declined due to deliberate loan book shrinkage, and the subsidiary's qualified audit opinion remains a concern. The bank is on a recovery trajectory but needs to sustain earnings momentum to reach a 1% ROA.
Key Investment Insights
Key Positives
- NIM proxy (NII/Interest Earned) expanded 170 bps QoQ to 41.42% and 359 bps YoY from 37.83%
- Cost-to-income ratio improved to 57.14% from 62.28% in Q4FY26 and 62.23% in Q1FY26
- GNPA fell to 3.25% from 3.43% QoQ and 3.64% YoY; NNPA fell to 0.95% from 1.00% QoQ and 1.12% YoY
- PPOP grew 8.03% YoY and 20.83% QoQ to Rs.2,773.45 Cr
- PAT surged 71.68% YoY to Rs.1,037.05 Cr, with EPS at Rs.13.31 vs Rs.7.75 in Q1FY26
- CAR of 17.15% (CET1 16.10%) remains strong and above regulatory minimums
Risk Factors
- Total income declined 9.18% YoY to Rs.13,096.47 Cr, driven by loan book shrinkage
- Other income fell 17.17% YoY to Rs.1,786.53 Cr
- Treasury segment results declined 49.88% YoY to Rs.537.41 Cr
- Subsidiary BFIL received a qualified audit opinion (continued from prior quarters)
- Co-lending microfinance portfolio has a high NPA of 9.7% (Rs.24.81 Cr out of Rs.255.99 Cr)
- ROA annualized at 0.78% remains below the implied 1% target
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.